According to DelveInsight, the Schizophrenia Market is projected to expand in the forthcoming years due to the growing prevalence of schizophrenia patients in the 7MM (Seven Major Markets) and the anticipated introduction of emerging products such as Roluperidone (MIN-101), Dexmedetomidine (BXCL501), Pimavanserin, Risperidone ISM (DORIA), and other products poised for deeper penetration into the 7MM markets.
Currently, numerous FDA-approved products are available for schizophrenia treatment, with several potential drugs in the pipeline expected to launch soon. Among the notable therapies in development are Doria (risperidone ISM), Roluperidone (MIN-101), Dexmedetomidine (BXCL501), SEP363856, Pimavanserin, BI 425809, GWP42003-P, KarXT (a fixed combination of xanomeline and trospium chloride), Evenamide, LYN-005, and others.
Furthermore, leading pharmaceutical and biotech companies active in the Schizophrenia therapeutics market include Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.
DelveInsight’s “Schizophrenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Schizophrenia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Schizophrenia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Schizophrenia Overview
Schizophrenia, a severe mental illness, disrupts cognitive clarity, emotional management, decision-making, and interpersonal connections. This complex, chronic condition affects approximately one percent of Americans.
While schizophrenia can manifest at any age, onset typically occurs in the late teens to early twenties for men and late twenties to early thirties for women. Diagnosis before age 12 or after age 40 is rare.
The disorder doesn’t stem from a single genetic variation but arises from a intricate interplay of genetics and environmental factors. Although it affects 1% of the general population, the risk significantly rises with a family history of psychosis. Roughly 10% of individuals with a first-degree relative, such as a parent or sibling, experience schizophrenia.
Schizophrenia Market Key Facts
-
In 2021, the total Schizophrenia market size was USD 8,664.6 million, which is expected to rise during the study period (2019–2032).
-
The total market size of Schizophrenia in the United States was USD 5,203.7 million in 2021.
-
In the EU5, the total market size of Schizophrenia was USD 2,547.3 million in 2021.
-
In 2021, the Schizophrenia prevalent cases were found to be around 6.27 million in the 7MM.
-
According to DelveInsight, in the year 2021, the total prevalent cases of Schizophrenia were 2.97 million in the United States, which is expected to grow during the study period, i.e., 2019–2032.
-
EU5 countries occupied approximately 33.8% of the diagnosed patient pool amongst 7MM in 2020.
-
In the year 2021, the total prevalent cases of Schizophrenia were 1.08 million cases in Japan which is expected to grow during the study period, i.e., 2019–2032.
-
On January 15, 2023, Luye Pharma Group (Luye Pharma) announced that the U.S. Food and Drug Administration (FDA) had approved Rykindo® (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.
-
On October 28, 2022, Sosei Group Corporation announced that the first patient had been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia. NBI-1117568 is an investigational, muscarinic M4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Schizophrenia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Schizophrenia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Schizophrenia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Schizophrenia Epidemiology Segmented by –
-
Prevalent Cases of schizophrenia in the 7MM (2019-32)
-
Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)
-
Age-specific Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)
-
Gender-specific Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)
-
Severity-specific Diagnosed Prevalent cases of schizophrenia in the 7MM (2019-32)
Schizophrenia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to be launched during the study period. The analysis covers the Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Schizophrenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Schizophrenia Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/schizophrenia-market
Schizophrenia Therapeutics Market
The primary medications employed in schizophrenia treatment are known as antipsychotics, primarily targeting the positive symptoms of the disorder. Response to antipsychotic drugs varies from person to person, often necessitating trials of multiple medications to identify the most suitable one. It’s crucial to maintain medication even after symptom alleviation, as discontinuation increases the risk of psychosis recurrence, with each subsequent episode potentially escalating in severity.
To improve the treatment scenario, several major pharma and biotech giants are actively working in the Schizophrenia Therapeutics Market. There are approx. 70+ key companies developing therapies for Schizophrenia. Currently, Otsuka Pharmaceutical is leading the therapeutics segment with its Schizophrenia drug candidates in the most advanced stage of clinical development.
Leading Companies in the Schizophrenia Therapeutics Market Include:
-
Boehringer Ingelheim
-
Karuna Therapeutics
-
Acadia Pharmaceuticals
-
Reviva Pharmaceuticals
-
Sunivion
-
PsychoGenics
-
Otsuka Pharmaceuticals
-
Neurocrine Biosciences
-
Takeda
-
Minerva Neurosciences
-
Newron Pharmaceuticals
-
Lyndra Therapeutics
-
Pharmaceuticals Laboratories
-
Cerevel Therapeutics
-
And Many Others
Schizophrenia Therapies Covered in the Report Include:
-
Backup modulators: Autifony Therapeutics
-
M4 PAM: Addex Therapeutics
-
Ralmitaront: Roche
-
MK-8189: Merck Sharp & Dohme
-
Ulotaront: Sunovion Pharmaceuticals
-
Iclepertin: Boehringer Ingelheim
-
CY 6463: Ironwood Pharmaceuticals
-
ML-007: MapLight Therapeutics
-
AVP-786: Avanir Pharmaceuticals
-
Ulotaront: Otsuka Pharmaceutical
-
Luvadaxistat: Takeda
-
CY6463: Cyclerion Therapeutics
-
AVP 786: Avanir Pharmaceuticals
-
And Many More
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/schizophrenia-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Schizophrenia Competitive Intelligence Analysis
4. Schizophrenia Market Overview at a Glance
5. Schizophrenia Disease Background and Overview
6. Schizophrenia Patient Journey
7. Schizophrenia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Schizophrenia Treatment Algorithm, Current Treatment, and Medical Practices
9. Schizophrenia Unmet Needs
10. Key Endpoints of Schizophrenia Treatment
11. Schizophrenia Marketed Products
12. Schizophrenia Emerging Drugs and Latest Therapeutic Advances
13. Schizophrenia Seven Major Market Analysis
14. Attribute Analysis
15. Schizophrenia Market Outlook (In US, EU5, and Japan)
16. Schizophrenia Access and Reimbursement Overview
17. KOL Views on the Schizophrenia Market
18. Schizophrenia Market Drivers
19. Schizophrenia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Download the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/schizophrenia-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/